Santaris Presents Data on Tiny LNAs for miRNA Family Inhibition
October 28, 2010
Santaris Presents Data on Tiny LNAs for miRNA Family Inhibition
In some cases, knocking down an entire family of microRNAs will be required to see a therapeutic benefit, according to Santaris CSO Henrik Orum. To address this issue, the company has been developing 8 nucleotide-long LNAs that are perfectly complementary to an miRNA seed region.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- With Positive Phase II Data on HCV Drug, Santaris Aims for Another Clinical Trial by the Summer
April 26, 2012 / Gene Silencing News - Arbiter Settles Santaris-Exiqon LNA Dispute; Each Firm Claims Victory
October 13, 2011 / Gene Silencing News - Santaris Releases Phase II Data Showing Its HCV Drug Is Well Tolerated, Effective
October 6, 2011 / Gene Silencing News - Santaris, CSHL Study Supports Tiny LNAs' Ability to Inhibit Entire miRNA Family
March 24, 2011 / Gene Silencing News - UNC Researchers Report New Details on Role of miR-122 in HCV
December 20, 2012 / Gene Silencing News